Is orforglipron a peptide?

No. It is a small molecule with no peptide bonds. That is the single most important technical fact about it and the reason it survives the stomach without an absorption enhancer.

Can I get Foundayo on the NHS?

Not at present. It holds a UK marketing authorisation but has not completed NICE appraisal; guidance is expected on 18 November 2026.

Does this approval change retatrutide's status?

No. Retatrutide remains investigational and is not authorised by the MHRA, EMA or FDA. The two compounds are at completely different regulatory stages.

Is orforglipron the first oral GLP-1?

It is not the first oral GLP-1 medicine — oral semaglutide preceded it — but it is the first oral GLP-1 agonist that is not a peptide, and the first authorised in Europe without food and water restrictions.

Research & Regulatory News

Orforglipron (Foundayo): The MHRA Approval, Explained

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-224 cited sources

On 10 August 2026 the MHRA authorised orforglipron, marketed as Foundayo by Eli Lilly, making the United Kingdom the first country in Europe to license the tablet. It is a once-daily oral GLP-1 receptor agonist approved for weight management and for glycaemic control in type 2 diabetes. It is not yet available on the NHS.

Key facts

Authorised: 10 August 2026 (MHRA)
Brand name: Foundayo
Developer: Eli Lilly and Company
Class: Oral small-molecule GLP-1 receptor agonist
Administration: Once-daily tablet, no food or water restrictions
First in Europe: Yes — no EU regulator had authorised it at the time
NHS status: Not available; NICE guidance expected 18 November 2026

What exactly was approved?

The MHRA granted marketing authorisation for orforglipron under the brand name Foundayo on 10 August 2026. The authorisation covers two distinct populations. The first is weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI between 27 and 30 where at least one weight-related comorbidity is present, used alongside a reduced-calorie diet and increased physical activity. The second is improving glycaemic control in adults with insufficiently controlled type 2 diabetes.

Why the approval was treated as significant

Two features made this a widely covered decision rather than a routine authorisation. The UK moved ahead of the European Medicines Agency, which is unusual for a product of this profile and was framed by the MHRA as a deliberate regulatory position. More importantly, orforglipron is taken as an ordinary tablet at any time of day, with no fasting window and no requirement to take it with a set volume of water — a practical difference from the oral peptide products that preceded it.

What the Phase 3 data showed

The pivotal obesity data were published in the New England Journal of Medicine on 16 September 2025. Over 72 weeks, mean weight reduction was 7.5% on 6 mg, 8.4% on 12 mg and 11.2% on 36 mg, against 2.1% on placebo. A separate study, ACHIEVE-3, reported in February 2026 that orforglipron produced greater weight reduction than oral semaglutide in adults with insufficiently controlled type 2 diabetes.

How it compares with the injectable incretins

It does not match them on magnitude, and the trial data do not claim to. The headline reductions from tirzepatide and from retatrutide's Phase 3 programme are substantially larger. Orforglipron's case rests on route of administration rather than effect size: an oral tablet with no absorption enhancer and no dosing ritual addresses a different problem from the one a weekly injection solves.

Reported adverse effects

The adverse-effect profile is recognisably that of the GLP-1 class and is dominated by gastrointestinal events: nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain were the most commonly reported. This is consistent with the mechanism rather than a surprise finding.

Availability in the UK

Authorisation is not the same as NHS funding. Foundayo is licensed but is not currently available through the NHS; that decision follows a separate appraisal by the National Institute for Health and Care Excellence, with guidance expected on 18 November 2026. Until then, access in the UK is through private prescription.

Quick reference

	Orforglipron (Foundayo)	Retatrutide
Molecule type	Non-peptide small molecule	39-residue peptide
Receptors	GLP-1 only	GIP / GLP-1 / glucagon
Route	Oral tablet, once daily	Subcutaneous, once weekly (trials)
UK status	Authorised 10 Aug 2026	Investigational — not authorised
Available on NHS	No — NICE guidance pending	No

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is orforglipron a peptide?: No. It is a small molecule with no peptide bonds. That is the single most important technical fact about it and the reason it survives the stomach without an absorption enhancer.
Can I get Foundayo on the NHS?: Not at present. It holds a UK marketing authorisation but has not completed NICE appraisal; guidance is expected on 18 November 2026.
Does this approval change retatrutide's status?: No. Retatrutide remains investigational and is not authorised by the MHRA, EMA or FDA. The two compounds are at completely different regulatory stages.
Is orforglipron the first oral GLP-1?: It is not the first oral GLP-1 medicine — oral semaglutide preceded it — but it is the first oral GLP-1 agonist that is not a peptide, and the first authorised in Europe without food and water restrictions.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum